PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trialAndrea Necchi, Filippo de Braud, Patrizia Giannatempo et al.|Investigational New Drugs|2014Cited by 54
Hyperprogression during immuno-checkpoint inhibitors (ICIs): A clinically significant problem?Elena Farè, Filippo de Braud, Michele Del Vecchio et al.|Annals of Oncology|2018Cited by 2